Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593811 · ClinicalTrials.gov registry record · Early Phase 1
Noninvasive Markers of Functional Nausea in Children
A Early Phase 1 study of Nausea, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT03593811: Active Early Phase 1 study of Nausea, sponsored by Vanderbilt University Medical Center.
NCT03593811 is a Early Phase 1 study of Nausea that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 42 participants, below the 242-participant average among 17 other Nausea trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03593811, a Early Phase 1 study of Nausea, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers propose to study how functional nausea in adolescents may be characterized noninvasively by the use of multichannel electrogastrogram (EGG) and magnetogastrogram (MGG) recordings.
Primary Outcome
Determine if there are differences in the slow wave activity in healthy versus disease stomach in the pediatric population. The percentage of normal slow waves (PNSW) will be used for comparison. PNSW is computed as the relative time of recording containing slow waves with a dominant frequency between 2-4 cpm from centrally-located EEG and MGG channels.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Questionnaires
- DIAGNOSTIC_TEST 4 channel electrogastrogram (EGG)
- DIAGNOSTIC_TEST 36 channel high resolution electrogastrogram (HR-EGG)
- DIAGNOSTIC_TEST Magnetogastrogram (MGG)
- DIAGNOSTIC_TEST Electrocardiogram (EKG)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-08-03 |
| Est. Completion | 2026-08-31 |
| Phase | Early Phase 1 |
What the registry record for NCT03593811 still lists
NCT03593811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 242-participant average among 17 other Nausea trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Nausea appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires is the first listed.
NCT03593811 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03593811 about?
NCT03593811 is a clinical study titled "Noninvasive Markers of Functional Nausea in Children". The researchers propose to study how functional nausea in adolescents may be characterized noninvasively by the use of multichannel electrogastrogram (EGG) and magnetogastrogram (MGG) recordings.
What is the current status of trial NCT03593811?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 42 participants. The study started on 2018-08-03. Estimated completion is 2026-08-31.
What conditions does trial NCT03593811 study?
This clinical trial studies the following conditions: Nausea.
What interventions are being tested in trial NCT03593811?
The interventions under investigation include: Questionnaires (DIAGNOSTIC_TEST), 4 channel electrogastrogram (EGG) (DIAGNOSTIC_TEST), 36 channel high resolution electrogastrogram (HR-EGG) (DIAGNOSTIC_TEST), Magnetogastrogram (MGG) (DIAGNOSTIC_TEST), Electrocardiogram (EKG) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03593811?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03593811 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03593811's enrollment target sits among peer trials
42 16th of 17 higher than 2 of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
-
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
RECRUITING · Phase 2
-
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI